Under the category of the Generic Medicines are listed the medicines which contain the same active substance under the same pharmaceutical form as the innovative/brand medicine and are marketed after their patent/exclusivity expiry. Members of Farmavita.net are invited to publish their out-license offers in this Category.
Member of Farmavita:net offer Dossier and license for Epoprostenol
CTD with supply agreement and marketing authorization
Epoprostenol 0.5 mg and 1.5 mg (Powder and Solvent for Solution for Infusion)
Epoprostenol is indicated for:
Pulmonary Arterial Hypertension Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ociated with connective tissue diseases) in patients with WHO Functional Cl III-IV symptoms to improve exercise capacity.
Renal Dialysis Epoprostenol is indicated for the use in haemodialysis in emergency situations when use of heparin carries a high risk of causing or exacerbating bleeding or when heparin is otherwise contraindicated.